We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the latest close session, Merck (MRK - Free Report) was up +1.07% at $149.88. The stock outpaced the S&P 500's daily gain of 0.58%. Elsewhere, the Dow saw an upswing of 0.69%, while the tech-heavy Nasdaq appreciated by 1.05%.
The pharmaceutical company's stock has dropped by 1.73% in the past month, falling short of the Medical sector's gain of 3.5% and the S&P 500's gain of 0.97%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on October 29, 2026. The company is expected to report EPS of $2.12, down 17.83% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $17.23 billion, showing a 0.25% drop compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.66 per share and a revenue of $67.1 billion, indicating changes of -70.38% and +3.21%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.83% lower. Merck currently has a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Merck is holding a Forward P/E ratio of 55.8. This signifies a premium in comparison to the average Forward P/E of 17.25 for its industry.
One should further note that MRK currently holds a PEG ratio of 6.85. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.04.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 219, putting it in the bottom 11% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Laps the Stock Market: Here's Why
In the latest close session, Merck (MRK - Free Report) was up +1.07% at $149.88. The stock outpaced the S&P 500's daily gain of 0.58%. Elsewhere, the Dow saw an upswing of 0.69%, while the tech-heavy Nasdaq appreciated by 1.05%.
The pharmaceutical company's stock has dropped by 1.73% in the past month, falling short of the Medical sector's gain of 3.5% and the S&P 500's gain of 0.97%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on October 29, 2026. The company is expected to report EPS of $2.12, down 17.83% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $17.23 billion, showing a 0.25% drop compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.66 per share and a revenue of $67.1 billion, indicating changes of -70.38% and +3.21%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Merck. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 3.83% lower. Merck currently has a Zacks Rank of #5 (Strong Sell).
Looking at its valuation, Merck is holding a Forward P/E ratio of 55.8. This signifies a premium in comparison to the average Forward P/E of 17.25 for its industry.
One should further note that MRK currently holds a PEG ratio of 6.85. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.04.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 219, putting it in the bottom 11% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.